Department of Internal Medicine F-Recanati, Rabin Medical Center, Beilinson Hospital, Petah Tiqva, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Tel Aviv, Israel.
Br J Clin Pharmacol. 2021 Jul;87(7):2902-2906. doi: 10.1111/bcp.14703. Epub 2021 Jan 7.
Metamizole is commonly used as analgesic and antipyretic drug. The use of metamizole is prohibited in several countries due to its rare side effect of neutropenia and even agranulocytosis. Among the many symptoms of COVID-19, fever and diffuse pain predominant and therefore it can be assumed that metamizole may be widely used in the current epidemic period. So far, there have been no reports on the safety of metamizole in COVID-19 patients. We describe a series of 3 patients who developed severe neutropenia under metamizole treatment, raising a concern of a possible increased risk of this side effect among COVID-19 patients.
甲灭酸通常被用作止痛和退热药物。由于其罕见的副作用中性粒细胞减少症甚至粒细胞缺乏症，在一些国家已经禁止使用甲灭酸。在 COVID-19 的众多症状中，发热和弥漫性疼痛为主，因此可以假设在当前流行期间甲灭酸可能被广泛使用。到目前为止，还没有关于 COVID-19 患者使用甲灭酸的安全性报告。我们描述了 3 例患者在甲灭酸治疗下发生严重中性粒细胞减少症的病例，这引起了人们对 COVID-19 患者中这种副作用风险增加的关注。
